U.S. markets open in 8 hours
  • S&P Futures

    4,389.25
    -4.50 (-0.10%)
     
  • Dow Futures

    34,844.00
    +10.00 (+0.03%)
     
  • Nasdaq Futures

    14,975.75
    -35.75 (-0.24%)
     
  • Russell 2000 Futures

    2,224.10
    +3.40 (+0.15%)
     
  • Crude Oil

    72.63
    +0.24 (+0.33%)
     
  • Gold

    1,815.10
    +15.40 (+0.86%)
     
  • Silver

    25.31
    +0.43 (+1.72%)
     
  • EUR/USD

    1.1861
    +0.0014 (+0.12%)
     
  • 10-Yr Bond

    1.2610
    0.0000 (0.00%)
     
  • Vix

    18.31
    -1.05 (-5.42%)
     
  • GBP/USD

    1.3937
    +0.0028 (+0.20%)
     
  • USD/JPY

    109.7160
    -0.1940 (-0.18%)
     
  • BTC-USD

    39,806.28
    -214.96 (-0.54%)
     
  • CMC Crypto 200

    932.49
    +2.56 (+0.28%)
     
  • FTSE 100

    7,016.63
    +20.55 (+0.29%)
     
  • Nikkei 225

    27,761.51
    +179.85 (+0.65%)
     

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Y-mAbs Therapeutics, Inc. (YMAB) Investigation

·2 min read

NEW YORK, NY / ACCESSWIRE / October 8, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Y-mAbs Therapeutics, Inc. ("Y-mAbs" or "the Company") (NASDAQ:YMAB). Investors who purchased Y-mAbs securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/ymab.

The investigation concerns whether Y-mAbs and certain of its officers and/or directors have violated federal securities laws.

On October 5, 2020, post-market, Y-mAbs issued a press release disclosing receipt of "a Refusal to File letter from the U.S. Food and Drug Administration (‘FDA') regarding the Biologics License Application (‘BLA') for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma, which was submitted in August 2020." Y-mAbs advised investors that "[u]pon preliminary review, the FDA determined that certain parts of the Chemistry, Manufacturing and Control (‘CMC') module and the Clinical module of the BLA require further detail." On this news, y-mAbs's stock price fell $3.57 per share, or 8.56%, to close at $38.13 per share on October 6, 2020.

If you are aware of any facts relating to this investigation, or purchased Y-mAbs shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/ymab. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/609777/Bronstein-Gewirtz-Grossman-LLC-Notifies-Investors-of-Y-mAbs-Therapeutics-Inc-YMAB-Investigation